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Abstract: Small, cysteine-rich and cationic antimicrobial proteins (AMPs) from filamentous
ascomycetes promise treatment alternatives to licensed antifungal drugs. In this study,
we characterized the Penicillium chrysogenum Q176 antifungal protein C (PAFC), which is
phylogenetically distinct to the other two Penicillium antifungal proteins, PAF and PAFB, that
are expressed by this biotechnologically important ascomycete. PAFC is secreted into the culture
broth and is co-expressed with PAF and PAFB in the exudates of surface cultures. This observation
is in line with the suggested role of AMPs in the adaptive response of the host to endogenous
and/or environmental stimuli. The in silico structural model predicted five β-strands stabilized by
four intramolecular disulfide bonds in PAFC. The functional characterization of recombinant PAFC
provided evidence for a promising new molecule in anti-Candida therapy. The thermotolerant PAFC
killed planktonic cells and reduced the metabolic activity of sessile cells in pre-established biofilms of
two Candida albicans strains, one of which was a fluconazole-resistant clinical isolate showing higher
PAFC sensitivity than the fluconazole-sensitive strain. Candidacidal activity was linked to severe cell
morphology changes, PAFC internalization, induction of intracellular reactive oxygen species and
plasma membrane disintegration. The lack of hemolytic activity further corroborates the potential
applicability of PAFC in clinical therapy.
Keywords: Penicillium chrysogenum antimicrobial protein C; PAFC; exudate; Candida albicans; reactive
oxygen species; plasma membrane permeabilization; cell death
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1. Introduction
The global incidence of fungal infections and the increasing resistance development pressure
the medical community to find alternatives to the currently used antimycotics. It is estimated that
over 300 million patients are affected by fungal infections and around 1.6 million deaths are caused by
fungal diseases annually [1].
The most prevalent human pathogenic yeasts which can cause life-threatening infections are the
Candida species, Candida albicans being the most prevalent one, but the incidence of infections caused by
non-albicans Candida species (NAC) is also increasing [2,3]. C. albicans can cause a wide range of human
infections, from recurring superficial nail, skin and mucosal infections to severe and life-threatening
systemic mycoses [4].
A limited number of licensed antifungal agents are available primarily due to the low number of
drug targets that are unique in fungi. This poses a challenge in the prevention and treatment of fungal
infections. Prolonged exposure to the currently available antifungal drugs can cause severe side-effects
and permanently damage the patients organs [5]. Current anti-Candida therapies include azoles,
echinocandins or amphotericin B, however the intensive application of azoles in clinical treatment
facilitates resistance development in these pathogens [6]. It is of utmost importance to identify new
antifungal agents with mechanisms of action that differ from those of existing drugs, with targets
that are unique to the fungal cell in order to be safely applicable to humans, and with low risk for
resistance development.
A promising source of new anti-Candida compounds are antimicrobial proteins (AMPs), secreted
by filamentous fungi of the class Eurotiomycetes [7]. One representative of this group, the antibiotic
producer Penicillium chrysogenum, harbors three genes that code for two well-characterized AMPs—the
P. chrysogenum antifungal protein (PAF) and antifungal protein B (PAFB) [8]—and a third putative
antifungal protein C (PAFC, Pc21g12970) [9]. Amino acid (aa) similarity analysis revealed that PAFC
is identical to the Pc-Arctin from an artic P. chrysogenum A096 isolate [10] and shares high similarity
with the “bubble protein” (BP) from Penicillium brevicompactum [11] and the Penicillium expansum
antifungal protein PeAfpC [12]. PAFC, Pc-Arctin, BP and PeAfpC belong to the so-called “BP cluster”,
which is named according to the first reported protein (BP) of this group. They are phylogenetically
different to the members of the PAF cluster that includes the two related P. chrysogenum AMPs, PAF and
PAFB [11,13]. The members of the BP cluster, however, are still less studied in terms of antifungal
activity and potential for application compared to other AMPs from filamentous ascomycetes.
The aim of this study was to characterize the antimicrobial protein PAFC of P. chrysogenum
strain Q176, a descendant of the original penicillin producer strain NRRL1951 and the ancestor of the
Wis54-1255 strain whose genome was sequenced [14,15]. For simplicity, we refer in the following to
P. chrysogenum Q176 as P. chrysogenum. We present an in silico analysis of the structural properties of
PAFC and, we report for the first time the gene expression of a BP cluster protein in submersed cultures
and surface colonies, its recombinant production and purification in high yield, and its growth inhibition
efficacy against the opportunistic human pathogen C. albicans. We have included in the analysis the
fluconazole sensitive C. albicans strain CBS 5982—referred in the following as C. albicansfluS—and
the fluconazole resistant clinical isolate 27700 (C. albicansfluR) [16]. We report that both strains were
susceptible to PAFC, with C. albicansfluR being more sensitive than C. albicansfluS. We have determined
the antifungal efficacy of PAFC against planktonic and sessile cells, the cellular uptake of PAFC, the
induction of intracellular reactive oxygen species (iROS) and the permeabilization of the plasma
membrane to the impermeable cell death indicating dye propidium iodide (PI). The anti-Candida
efficacy, thermotolerance and absence of hemolytic activity suggest that PAFC may be a potential
candidate next generation antifungal drug that is also effective against azole-resistant C. albicans strains.
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2. Materials and Methods
2.1. In Silico Structural Prediction of PAFC
In silico structural prediction was done based on the hypothetical protein annotated as
Pc21g12970 (National Center for Biotechnology Information (NCBI), accession number XP_002568323)
in Penicillium rubens Wisconsin 54-1255, which is a descendent of P. chrysogenum Q176 [14,15]. Full-length
protein aa sequence was submitted to the I-Tasser server [17] for prediction of the secondary and
tertiary protein structure. The crystal structure of the P. brevicompactum BP (PDB ID: 1uoy.pdb) was
used as template without alignment, due to high primary structure similarity. The resulting model was
chosen based on the Z-score and quality was energy minimized and refined with the ModRefiner [17].
The reliability of the calculated model was evaluated in Ramachandran plot analysis using a RAMPAGE
server [18]. The disulfide bond pattern was predicted with Disulfind [19]. To evaluate the reliability of
the predicted disulfide bond pattern, the distance between the bonded cysteine residues was analyzed
by X-walk [20] using the BP bond pattern as template. Protein model visualization was performed with
UCSF ChimeraX software [21]. Alignment of PAFC, PeAfpC and BP was realized with Jalview 2 [22]
and sequence colored according to ClustalX. The percent identity matrix between these three proteins
was calculated with ClustalW2 Multiple Sequence Alignment tool [23]. The physicochemical properties
of PAFC were determined with GRAVY calculator (available online: www.gravy-calculator.de),
ProtParam tool (available online: www.web.expasy.org), and ProteinCalculator v3.4 (available online:
www.protcalc.sourceforge.net).
2.2. Strains and Growth Conditions
Fungal strains used in this study are listed in Supplementary Materials, Table S1 and the
composition of the media is described in Supplementary Materials, Table S2. For the generation of
conidia, P. chrysogenum Q176 was grown on 1 × PcMM for 96 h at 25◦C. Conidia were harvested and
washed in spore buffer (0.9% NaCl (w/v), 0.01% Tween (v/v)) before use. Germlings were generated by
growing conidia in 1 × PcMM at 25◦C in static culture until the germ tubes were twice the length of
the conidia diameter (11 h). For P. chrysogenum submersed shaking cultures 200 mL 1 × PcMM was
inoculated with 2 × 108 spores and cultivated for up to 96 h at 25 ◦C and 200 rpm. Synchronized
surface cultures were generated on 1 × PcMM, containing 1.5% (w/v) agar at 25 ◦C as described in
Hegedüs et al., 2011 [24]. For the generation of fungal exudates, 5 µL aliquots containing 1 × 106
P. chrysogenum conidia were point inoculated on 1 × PcMM or double-concentrated PcMM (2 × PcMM),
containing 1.5% (w/v) agar. The surface cultures were grown for up to 144 h at 25 ◦C in a box lined
with wet paper towels. Single colonies of Candida strains grown on potato dextrose broth (PDB)
agar plates (Sigma-Aldrich, St. Louis, MO, USA) were used to inoculate 10 mL ten-fold diluted PDB
(0.1 × PDB). After overnight cultivation at 30 ◦C and 160 rpm the cells were washed in 0.1 × PDB before
experimental use.
2.3. Detection of PafC mRNA
The expression of pafC was investigated in conidia, germlings, and mycelia of submersed and
synchronized surface cultures of P. chrysogenum. Total RNA was extracted from cells with TRI Reagent
(Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instruction. Ten µg RNA per
lane were loaded onto a 1.2% (v/v) formaldehyde gel, electrophoresed and blotted onto a Hybond
N membrane (Amersham Biosciences, Little Chalfont, UK). The pafC transcripts were detected with
a digoxigenin-labelled hybridization probe (Roche, Basel, Switzerland) amplified by PCR (Table S3)
from pafC cDNA using pafC specific primers (Table S4).
2.4. Detection of Native PAFC
Submersed cultures of P. chrysogenum were prepared as described above and the supernatant
was used for Western blot analysis at different time points. Fungal exudates, the liquid secreted
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underneath the fungal colony and the droplets on top of the colony, were harvested as described in
Supplementary Materials (experimental procedures; Figure S1) after 120 h of incubation. Samples (20µL
per lane) were loaded onto a 18% (w/v) SDS-polyacrylamide gel, electrophoresed and Western blotting
performed as described (Supplementary Materials, experimental procedures). PAFC was detected
using rabbit anti-PeAfpC serum (1:2500) [12]. PAF and PAFB in the exudate were detected using
IgG purified rabbit anti-PAF serum (1:500) [25] and rabbit anti-PAFB serum (1:1000) [9], respectively
(Supplementary Materials, experimental procedures).
2.5. Generation of Recombinant PAFC
Recombinant PAFC was prepared using a P. chrysogenum-based expression system [26]. The cloning
of expression vector pSK275_pafC (Figure S2) and transformation into the P. chrysogenum ∆paf mutant
strain [26] are described in Supplementary Materials (experimental procedures). The strain with the
highest PAFC content in the culture broth was named P. chrysogenumOEpafC and used for large-scale
expression. The cell-free supernatant was processed as described previously [26] with minor
modification. The pH of the supernatant was adjusted to 4.0 with 1 M citric acid before it was
filter sterilized, degassed and loaded onto a BioPro S30 cation exchange column (YMC CO. LTD,
Kyoto, Japan). The column was washed with 0.1 M equilibration buffer (0.1 M citrate buffer pH 4,
0.5 M EDTA, 25 mM NaCl) and PAFC was eluted with 0.1 M elution buffer (0.1 M citrate buffer pH 4,
100 mM NaCl). Fractions containing the protein peak were checked for PAFC content and purity on a
18% (w/v) SDS-polyacrylamide gel and by silver staining. The pure PAFC containing fractions were
concentrated and dialyzed against ddH2O using a Vivaspin®500 device (3 kDa MWCO; GE Healthcare,
Chicago, IL, USA). The identity of PAFC was verified by electrospray ionization mass spectroscopy
(ESI-MS) (Protein Micro-Analysis Facility; Biocenter, Medical University of Innsbruck) and the purity
of the protein confirmed by reverse-phase high-performance liquid chromatography (RP-HPLC).
The RP-HPLC run was performed on a Phenomenex Jupiter 10 µM C18 300 Å column using the
following eluent system: (A) 0.1% (v/v) trifluoroacetic acid (TFA); (B) 80% (v/v) acetonitrile and 0.1%
(v/v) TFA. A linear gradient of 15–40% (B) in 25 min was applied at a flow rate of 1.0 mL·min−1.
2.6. Determination of Anti-Candida Activity
2.6.1. Broth Microdilution Assays
For determination of the inhibitory concentration that reduces growth ≥90% (IC90), 100 µL of yeast
cells (1× 104 mL−1) were mixed with 100µL of PAFC in increasing concentrations (0–20µM) in 0.1×PDB
in 96-well, flat-bottom microtiter plates (Thermo Scientific, Waltham, MA, USA). Amphotericin B,
nystatin and fluconazole were purchased from Sigma-Aldrich (St. Louis, MO, USA) and tested in a
concentration range of 0–125 µg mL−1. To study the effect of serum and ions on the antifungal activity,
increasing concentrations of heat-inactivated fetal calf serum (5–15%) and NaCl, CaCl2 and MgCl2
(1.25–10 mM) were included in broth microdilution assays together with 1 × IC90 PAFC and C. albicans
in 0.1 × PDB as described above. C. albicans cells exposed to the supplements without PAFC served as
controls. The thermal tolerance of PAFC was studied by incubating the protein for 5 min at 95 ◦C and
determining the antifungal activity immediately after cooling to 25 ◦C. PAFC that had not been exposed
to serum, ions or heat served as full-activity control. The optical density (OD620nm) was determined
after static cultivation for 24 h at 30 ◦C using a multi-mode microplate reader (FLUOstar Omega,
BMG Labtech, Ortenberg, Germany) operating in well-scanning mode. All assays included a blank
(medium without cells) and an untreated growth control representing 100% growth. All experiments
were done using technical triplicates and repeated at least twice.
2.6.2. Determination of Colony Forming Units (CFU)
To determine the killing efficacy of PAFC, C. albicans planktonic cells from an overnight culture
were diluted to 2 × 105 cells·mL−1 in 0.1 × PDB and treated with 1 × IC90 (2.5 µM), 2 × IC90 (5 µM) or
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4 × IC90 (10 µM) PAFC for 1 h, 8 h and 24 h at 30 ◦C under continuous shaking (160 rpm). Untreated
cells were used as a growth control. Cells were collected by centrifugation, resuspended in 1 mL
0.1 × PDB and a serial dilution up to 10−6 was prepared. From each dilution, 100 µL were streaked
onto 2% (w/v) PDB agar plates and incubated at 30 ◦C for 24 h before the colony forming units (CFU)
were counted. The CFU of the untreated control was set at 100%. All experiments were done using
technical quadruplicates and repeated twice.
To evaluate the activity of PAFC on sessile cells of C. albicans, biofilm formation was induced
by distributing 100 µL aliquots of a cell suspension (1 × 106 cells·mL−1 in 0.1 × PDB) in the wells of
a 96-well, flat-bottom microtiter plate (Thermo Scientific, Waltham, MA, USA) followed by a static
incubation for 24 h at 30 ◦C. The resulting biofilm was checked microscopically for cell attachment and
pseudo-hyphae formation before treatment. The biofilm was gently washed with 0.1 × PDB before
100 µL of 1 × IC90 (2.5 µM) and 10 × IC90 (25 µM) PAFC was added in respective wells. For the negative
control, the cells were incubated with 0.1 × PDB and for the positive control the cells were exposed to
10 µg·mL−1 amphotericin B. After 24 h of incubation, the biofilm was disrupted by vigorous pipetting,
and 10 µL of the detached cells were mixed with 40 µL fresh 0.1 × PDB. Serial dilution of this sample
up to 10−6 were made and 100 µL streaked out onto 2% (w/v) PDB agar plates and incubated at 30 ◦C
for 24 h for CFU determination. The CFU of the untreated control was set at 100%. All experiments
were conducted using technical triplicates and repeated twice.
2.7. Scanning Electron Microscopy (SEM)
C. albicans cells (5 × 105, diluted in 0.1 × PDB) from an overnight liquid culture were incubated
with 1 × IC90 PAFC for 1 h, 12 h, and 24 h at 30 ◦C under continuous shaking at 160 rpm. Untreated cells
were used as a negative control. Samples were washed, resuspended in phosphate buffered saline (PBS)
and 8 µL samples spotted onto a silicon disc coated with 0.01% (w/v) poly-l-lysine (Merck Millipore,
Billerica, MA, USA). Cells were fixed with 2.5% (v/v) glutaraldehyde and 0.05 M cacodylate buffer
(pH 7.2) in PBS overnight at 4 ◦C. The discs were washed twice with PBS and dehydrated with a
graded ethanol series (30%, 50%, 70%, 80%, 100% ethanol (v/v), for 1.5 h each at 4 ◦C). Samples of
untreated cells served as negative control. The samples were dried with a critical point dryer, followed
by 12 nm gold coating (Quorum Technologies, Laughton, East Sussex, UK) and observed under a JEOL
JSM-7100F/LV scanning electron microscope (JEOL Ltd., Tokyo, Japan).
2.8. Fluorophore-Labeling of PAFC
For visualization in uptake studies PAFC was labeled with the green fluorophore BODIPY™ FL
EDA (Bd) (Invitrogen, Carlsbad, CA, USA) as described previously [27]. In brief, 0.4 mM PAFC was
labeled with 10 mM Bd in the presence of 10 mM EDAC and 5 mM Sulfo-NHS (Invitrogen, Carlsbad,
CA, USA) in 100 M MES-buffer (pH 4.5). The reaction mixture was incubated with continuous
shaking at 200 rpm overnight at 25 ◦C in the dark. The labeled AMP (PAFC-Bd) was dialyzed against
ddH2O to remove excess Bd and concentrated using Amicon®Ultra centrifugal filters (3 kDa MWCO;
Merck Millipore, Burlington, MA, USA). The antifungal activity of PAFC-Bd was tested by broth
microdilution assay as described above.
2.9. Confocal Laser Scanning Microscopy (CLSM)
Candida cells adjusted to 2 × 105 cells·mL−1 in 0.1 × PDB were treated with 1 × IC90 PAFC-Bd
(2.5 µM) for 3 h and 6 h at 30 ◦C under continuous shaking at 160 rpm. Untreated cells were used
as negative control. Samples were washed with PBS and stained consecutively with 5 µg mL−1 PI
(Sigma-Aldrich, St. Louis, MO, USA) and 5 µg·mL−1 calcofluor white (CFW) (Sigma-Aldrich, St. Louis,
MO, USA) for 10 min at room temperature in the dark. After washing with PBS, samples were mounted
on a glass slide, covered with 2% (w/v) agar slices and observed with an Olympus Fluoview FV 1000
confocal laser microscope with 60× magnification objective (Olympus, Shinjuku, Japan). A 488 nm
laser was used for excitation. The excitation and emission wavelengths were 380 nm and 475 nm
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for CFW, 504 nm and 512 nm for PAFC-Bd and 535 nm and 617 nm for PI, respectively. Sequential
scanning was used to avoid crosstalk between the fluorescent dyes.
2.10. Fluorescence Activated Cell Sorting (FACS)
Candida cells diluted to 2 × 105 cells·mL−1 in 0.1 × PDB were exposed to 1 × IC90 PAFC for 1 h,
8 h and 24 h at 30 ◦C under continuous shaking at 160 rpm. Untreated cells were used as negative
control and 70% (v/v) EtOH treated cells as positive control for PI staining. The cells were washed in
PBS, collected by centrifugation at 11,000× g for 5 min and stained with 5 µg·mL−1 PI for 10 min at
room temperature. PI positive cells were counted by a FlowSight imaging flow cytometer (Amins,
Merck Millipore, Billerica, MA, USA) with at least 1000 cells were counted per run. For data analysis,
the Image Data Exploration and Analysis software (IDEAS; Amins, Millipore, Billerica, MA, USA) was
applied. Gates for the data analyses were established according to the unstained control. Experiments
were performed using independent triplicates.
2.11. Hemolytic Activity
The hemolytic potential of PAFC was evaluated on Columbia blood agar plates (VWR, Randnor,
PA, USA). Sterile filter discs (Ø6 mm) were put onto agar plates and loaded with 10 µL aliquots
containing 13 µg PAFC. Sterile water and 20% (v/v) Triton X-100 (10 µL each) served as controls.
Plates were incubated at 37 ◦C for 24 h before documentation.
2.12. Statistical Analysis
Data analyses were conducted with Microsoft Excel (2016, Version 16.16.16) software (Microsoft,
Redmond, WA, USA). For the calculation of significant differences between the data obtained from
treated samples vs. the untreated controls, a two-sample Student’s t-test was applied. p-values of ≤0.05
were considered as significant and p-values of ≤0.005 were considered as highly significant.
2.13. Image Processing
Images were processed and edited with Axiovision (Carl Zeiss GmbH, Oberkochen, Germany),
Fiji [28], GNU Image Manipulation Program (GIMP, version 2.8.10) and Microsoft Power Point
(Microsoft Corp.).
3. Results
3.1. In Silico Prediction of the PAFC Structure
The alignment of the pre-mature PAFC pre-pro protein sequence with that of PeAfpC from
P. expansum and BP from P. bevicompactum revealed 85.2% and 70.1% identity, respectively (Figure S3).
The mature PAFC is 64 aa long, has a predicted molecular mass of 6630 Da (assuming all cysteines in
reduced form) and is 100% identical to the Pc-Arctin of the arctic isolate P. chrysogenum A096 [10]. It has
82.8% and 79.7% identity to the mature form of PeAfpC and BP, respectively (Figure S3). All three
proteins possess two putative levomeric γ-core motifs (CX3-9CXGX1-3) [29], which are conserved
among the ascomycetous AMPs of the BP cluster [13]. One of them—positioned in the center of PAFC
(CDRTGIVECKG)—is highly conserved, and the second, shorter one with lower homology resides
near the C-terminus (CGGASCRG) (Figure 1A and Figure S3).
The in silico prediction of the PAFC tertiary structure gave a model showing high fold similarity
to the BP of P. brevicompactum [30]. The Ramachandran plot of the model showed 95.2% of the
aa positioned in energetically favored regions and three in the allowed regions (4.8%) (Figure S4).
The PAFC model exhibits five antiparallel β-strands (β1–β5), spanning His26–Cys28 (β1), Gly34–Lys39
(β2), Lys42–Asp48 (β3), Arg55–Val57 (β4) and Gly60–Arg63 (β5), which are connected by four loops
(L1–L4). The protein model shows an N-terminal three stranded β-sheet (β-sheet 1) with an N-terminal
extended structure and a C-terminal two stranded β-sheet (β-sheet 2). The γ-core motif in the protein
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center (Cys30–Lys39) encompasses L1 and β2, and the shorter γ-core motif (Cys49–Gly56) contains
a part of L3 and β4 (Figure 1B). As already shown for the BP protein [11] the β-pleated structure of
PAFC is stabilized by four intramolecular disulfide bonds that are formed between the eight cysteine
residues. The predicted disulfide bond pattern (Cys 3/30, Cys 18/38 Cys 28/54, Cys 49/64) of PAFC
follows the abcabdcd pattern of the BP [30]. The disulfide bonds Cys 3/30 and Cys 18/38 connect the
β-sheet 1 to the N-terminal extended region, while Cys 28/54 and Cys 49/64 connect β-sheet 1 with
β-sheet 2 (Figure 1C).
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γ-core motifs highlighted in red. (B) Rib o resen ation of PAFC in U SF Chimera protein
visualization and analysis software [21] depicting the structure of the β-strands (blue) and location of
the two γ-cores (red), the N- and C-terminus is indicated. (C) Disulfide bonding of PAFC is shown with
yellow sticks. (D) Surface representation of PAFC in two orientations colored according to electrostatic
potential (blue: electropositive, red: electronegative). The model depicted on the right side visualizes
the “mouth-like” cavity indicated by a black arrow in the left model. The basic aas surrounding
the opening and the aa forming the funnel base are indicated. (E) Distribution of hydrophobic and
hydrophilic patches on the surface of PAFC in two orientations colored according to the Kyte-Doolittle
scale (blue: hydrophilic, orange: hydrophobic). The aas forming the hydrophobic patches are indicated
in the model on the right.
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Analysis of the electrostatic surface distribution according to Coulomb’s law in UCSF Chimera
software [21] indicated that the putative PAFC structure has a cavity similar to BP [30]. The opening of
this “mouth-like” structure is dominated by basic aas (Arg12, Arg13, Arg25, Arg32) that are in highly
conserved positions in BP and PAFC, with Arg12, Phe27 and Trp43 form the funnel base (Figure 1D).
The opposite side has two negatively charged patches, a smaller one consisting of Asp24 and Glu37,
and a bigger one, consisting of Asp31, Asp48 and Glu45 (Figure 1D; Supplementary Materials,
Video S1). According to the Kyte-Doolittle scale [31], PAFC shows an amphipathic surface with the aas
Val9, Ile35/Ile46 and Val57 forming three hydrophobic patches (Figure 1E; Supplementary Materials,
Video S2).
3.2. Expression of PAFC in P. chrysogenum
Northern blot experiments indicated that the expression of the PAFC encoding gene (pafC) peaked
after 72 h of cultivation under standard submersed conditions (Figure 2A). Expression of pafC was also
detected in synchronized P. chrysogenum surface cultures and correlated with the onset of conidiation
(Figure S5), with gene expression reaching its maximum after 36 h of incubation (Figure 2B). No pafC
expression was detected in conidia or 11-h-old germlings. These results imply that PAFC is produced
under submersed and surface growth conditions in P. chrysogenum. To demonstrate PAFC in the fungal
culture broth, we performed a Western blot analysis (Figure 2C) probed with a rabbit polyclonal
antibody generated against the PAFC-related PeAfpC [12]. This antibody recognized the purified
recombinant PAFC (Figure S6) and did not bind to the purified recombinant PAF or PAFB (Figure 3B,
upper panel). A faint band with the molecular weight corresponding to mature native PAFC was
detected in the crude fermentation broth of submersed cultures after 72 h and 96 h of cultivation
(Figure 2C). However, the anti-PeAfpC antibody also bound to secreted proteins with molecular
weight > 6.6 kDa in the crude supernatant. This may be due to (I) the polyclonal character of the
anti-PeAfpC antibody [12] and (II) the low PAFC amount in the culture broth, which necessitated a
long development time to obtain a detectable signal intensity for the PAFC specific band.
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Figure 2. Expression of the PAFC encoding gene and protein. Total RNA was extracted from
(A) mycelium grown in submersed and (B) synchronized surface cultures up to 96 h. Tenµg of total RNA
was loaded per lane on a 1.2% denaturing agarose gel, blotted onto a nylon membrane and hybridized
with a pafC specific digoxigenin-labelled PCR probe (upper panels). Ethidium bromide-stained 26S
and 18S rRNA provide loading controls (lower panels). (C) For Western blot analysis, 20 µL of the
cell free supernatant from submersed cultures was loaded per lane, size fractionated on an 18% (w/v)
SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane. A polyclonal antibody
generated against PeAfpC was used to probe for PAFC. Recombinant PAFC (0.5 µg) was used as a
control for antibody binding. The black arrow indicates PAFC (6.6 kDa). LRM, low range rainbow
marker (GE Healthcare Life Sciences, Little Chalfont, UK). The molecular weight marker bands of
3.5 kDa and 8.5 kDa are indicated.
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3.3. Expression of PAFC, PAF and PAFB in Fungal Exudates
Seibold et al. (2011) [11] found the BP in exudates of P. brevicompactum surface cultures.
This prompted us to check the droplets formed on the colony surface of P. chrysogenum grown
on solid medium. These droplets emerged after 120 h of cultivation on colonies that had been point
inoculated on solid P. chrysogenum minimal medium (1 × PcMM). On this medium the droplets
formed a ring around the center of the P. chrysogenum colony (Figure 3A). These droplets originated
from the fungal exudate that the colony secreted basally. The amount of liquid underneath the
colony and the size of droplets could be augmented by cultivating P. chrysogenum on agar containing
double-concentrated nutrients (2 × PcMM) (Figure 3A). Here the droplets accumulated on top of the
colony. When the exudate that had formed underneath the colony after 96 h was harvested, no further
droplets emerged on top of the colony with further incubation (Figure S1), indicating the same origin
of the exudate and the droplets. After an extended incubation of 144 h the exudate had completely
disappeared (Figure S1). PAFC was detected by Western blot analysis in both, the exudate formed
underneath the colony and the droplets (Figure 3B). We also tested the samples for the presence of the
other two P. chrysogenum AMPs and could detect PAF and PAFB by using polyclonal anti-PAF and
anti-PAFB antibodies [9,25] (Figure 3B).
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LRM, low range rainbow marker (GE Healthcare Life Sciences, Little Chalfont, UK). The molecular
weight marker bands of 3.5 kDa and 8.5 kDa are indicated.
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3.4. Bulk Production and Purification of Recombinant PAFC
Figure 2C indicates that the amount of native PAFC in the supernatant of P. chrysogenum was
insufficient for purification and further functional investigations. Therefore, we expressed recombinant
PAFC using a P. chrysogenum-based expression system [26] by cloning pafC into the pSK275 vector
between the strong paf promoter and the paf terminator sequence (Figure S2). The P. chrysogenum ∆paf
strain transformed with linearized pSK275_pafC served as cell factory for PAFC expression [32,33].
The strain secreting the highest PAFC quantity (P. chrysogenumOEpafC) was selected for protein production
and PAFC was purified from 96 h cell culture supernatant by one-step cation-exchange chromatography
(Figure S7A). A protein yield of up to 105 ± 15 mg L−1 fermentation broth was obtained. RP-HPLC
gave a single elution peak suggesting high purity of the sample (Figure S7B). The identity of PAFC was
verified by ESI-MS. The detected mass of 6622 Da matched the predicted mass of oxidised PAFC which
contains four disulfide bonds and lacks the pre-pro sequence (Figure S7C).
3.5. Anti-Candida Activity of PAFC in Broth Microdilution Assays
The recombinant PAFC was tested for anti-Candida activity in broth microdilution assays and the
inhibitory concentration that reduces growth ≥90% (IC90) was determined (Table 1). PAFC inhibited
the growth of the Candida spp. tested (Table S1) at low µM concentrations, and the fluconazole
sensitive C. albicansfluS and a fluconazole resistant clinical isolate C. albicansfluR exhibited the same PAFC
sensitivity (IC90 2.5 µM) (Table 1 and Table S1). For comparison, we also tested the susceptibility of
Candida spp. for the commonly used antifungal drugs fluconazole, amphotericin B and nystatin (Table 1).
The C. albicansfluR strain still proliferated in the presence of the highest fluconazole concentration
tested (125 µg mL−1) which confirmed its resistance against this common drug under the experimental
conditions applied in this study.
Table 1. Inhibitory concentrations of PAFC and commonly used antifungal drugs reducing Candida
spp. growth ≥90% (IC90) §.
Microorganisms PAFC Fluconazole Amphotericin B Nystatin
Candida albicansfluS 2.50 (16.50) 6.37 (1.95) 0.02 (0.02) 2.11 (1.95)
Candida albicansfluR 2.50 (16.50) 408.50 (>125) 1.05 (0.97) 0.53 (0.49)
Candida glabrata 0.15 (0.99) 12.78 (3.91) 0.03 (0.03) 0.53 (0.49)
Candida guilliermondii 3.12 (20.59) 1.60 (0.49) 0.06 (0.06) 1.06 (0.98)
Candida krusei 2.50 (16.50) 51.08 (15.63) 0.06 (0.06) 1.06 (0.98)
Candida parapsilosis 0.04 (0.26) 12.78 (3.91) 8.45 (7.81) 1.06 (0.98)
§ Candida spp. (1 × 103 cells mL−1) were grown in 0.1 × PDB for 24 h at 30 ◦C under static conditions. IC90 was
defined as PAFC concentration that inhibits growth ≥90% compared to the untreated control. IC90 values are given
in µM (µg mL−1 in parenthesis).
3.6. Impact of PAFC on C. albicans Biofilm
We investigated the antifungal effect of PAFC on sessile cells of the most prevalent pathogen
in this group using C. albicansfluS and C. albicansfluR. A 24-h-old biofilm was treated with 1 × IC90
(2.5 µM) and 10 × IC90 (25 µM) PAFC because biofilms are generally less accessible to antifungal
compounds [34] and the established biofilm contains a higher cell number than the experiments
performed with planktonic cells.
The survival of the sessile cells evaluated by CFU determination using a plating assay revealed
that PAFC inhibited biofilm formation in a concentration dependent manner. Table 2 shows that the
number of viable C. albicansfluS cells decreased significantly after the 24-h treatment with 10 × IC90
PAFC compared to the untreated control. The C. albicansfluR seemed to be more sensitive because a
lower PAFC concentration (1 × IC90) significantly increased cell death. This was further aggravated
when PAFC was applied at 10 × IC90. In both strains, however, a PAFC concentration as high as
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10 × IC90 could not completely impede biofilm growth as shown with 10 µg mL−1 amphotericin B
(no growth).
Table 2. Survival of Candida albicans sessile cells after 24 h treatment with PAFC determined by
plating assay §.
Strain Untreated
PAFC
Amphotericin B 10 µg mL−1
1 × IC90 10 × IC90
Candida albicansfluS 100 ± 10.8 83.4 ± 3.0 47.0 ± 3.8 * 0 ± 0 **
Candida albicansfluR 100 ± 5.8 48.1 ± 2.2 ** 28.1 ± 4.5 ** 0 ± 0 **
§ Values of surviving cells are given in % CFU of the untreated control. * p ≤ 0.05 and ** p ≤ 0.005.
3.7. Effect of PAFC on the C. albicans Cell Morphology
The effect of PAFC on the morphology of C. albicansfluS and C. albicansfluR cells was evaluated
using SEM. Untreated control cells exhibited a typical ovoid shape with budding sites and a smooth
cell surface (Figure 4). In contrast, a 1 h treatment with 1 × IC90 PAFC (2.5 µM) showed cells with a
wrinkly surface and amorphous material on and between cells, which may indicate loss of osmotic
pressure and leakage of cell contents, respectively. With longer incubation time (12 h), C. albicans cells
showed severe signs of cell leakage and lost their ovoid shape. After 24 h morphologically intact
C. albicansfluS cells were observed again, suggesting that some cells survived the treatment and resumed
growth (Figure 4A). In contrast, C. albicansfluR cells still appeared severely damaged after 24 h of PAFC
exposure (Figure 4B).
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Figure 4. SEM analysis of the impact of PAFC on the C. albicans c r hology. (A) C. albicansfluS and (B)
C. albicansfluR cells were incubated with 1 × IC90 (2.5 µM) PAFC or without PAFC (untreated) for 1 h, 12 h
and 24 h at 30 ◦C with continuous shaking at 160 rpm. One representative image out of three replicates is
shown in overview and high magnification, respectively. Scale bars are indicated in the images.
3.8. Cellular Localization of PAFC and Cell Death Induction
To investigate whether PAFC interacts only with the outer cell layers (cell wall or plasma
membran ) o enters th cytosol f the C. albicans cells we use to detect PAFC labeled with the
green fluorophore BODIPY (PAFC-Bd). The fluorophore-labelling of PAFC had no advers impact
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on its antifungal activity. The application of 2.5 µM PAFC-Bd in a broth microdilution assay resulted
in C. albicans growth inhibition of 98.6%, which corresponded to the IC90 of PAFC. Co-staining
with the membrane impermeant fluorescent cell death dye PI visualized cells that were killed by
the interaction with PAFC-Bd. Cells were incubated for 3 h and 6 h to ensure that the PAFC-Bd
specific fluorescence signal was intense enough for visualization. After 3 h PAFC-Bd attached to the
outer layers of C. albicansfluS and this signal co-localized with the cell wall specific blue dye CFW
(Figure 5A). Intracellular fluorescent patches (subcellular structures) indicated that PAFC-Bd was
taken up by the cells without cell death induction (no PI signal). After 6 h the positively stained cells
showed the PAFC-Bd signal dispersed in the whole cell (cytoplasm) that coincided with a strong
intracellular PI signal, whereas cells exhibiting a PAFC-Bd signal that still localized in subcellular
structures remained PI-negative (Figure 5A). A similar uptake and intracellular staining pattern with
PAFC-Bd was observed with C. albicansfluR cells, although interaction of PAFC-Bd with cells could be
detected only at 6 h of incubation (Figure 5B). Localization of PAFC-Bd with the nuclei was excluded
when co-staining with the nuclei-specific dye Hoechst 33342 and imaged by fluorescence microscopy
(Supplementary Materials, experimental procedures; Figure S8). Taken together, these qualitative
microscopy-based data revealed that PAFC first enters sensitive cells before the plasma membrane is
compromised and cell death is induced. This suggests that an intracellular PAFC target may exist.
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Figure 5. CLSM analysis of the cell lar localizati n of PAFC and cell eath induction. Cells of
(A) C. albicansflu and (B) C. albicansfluR were exposed to 1 × IC90 PAFC-Bd (2.5 µM) for 3 h, 6 h and 12 h
and then stained with calcofluor white (CFW, 5 µg mL−1) and propidium iodide (PI, 5 µg mL−1) for
10 min. Control cells were left untreated. Sequential scanning was done for CFW (blue), PAFC-Bd (green)
and PI (red) at 405, 488 and 543 nm, respectively. White arrows indicate vacuoles, white arrowheads
dead cells. One representative image out of three replicates is shown. Scale bar, 5 µm.
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3.9. Candidacidal Efficacy of PAFC
The time course of cell death caused by PAFC was detected using the cell death specific dye PI
with FACS analysis (Table 3). Exposure of C. albicansfluS to 1 × IC90 (2.5 µM) PAFC resulted in a time
dependent increase in the proportion of PI positive cells after 1 h and 8 h of incubation. Interestingly,
after a 24 h incubation the number of cells with a PI-positive phenotype dropped below 1%, suggesting
that surviving cells had resumed growth. The treatment of C. albicansfluR with PAFC similarly induced
an increase in PI-positive cells between 1 h and 8 h of exposure, though in a slightly delayed manner.
In strong contrast to the C. albicansfluS, however, the percentage of C. albicansfluR cells with a PI-positive
phenotype further increased with time and reached more than 70% after 24 h, indicating that a high
proportion of cells suffered from plasma membrane permeabilization due to PAFC treatment.
Table 3. PI-positive C. albicans cells at 1 h, 8 h and 24 h of PAFC treatment evaluated by FACS analysis §.
Strain Untreated 1 h 8 h 24 h EtOH
C. albicansfluS 0.10 ± 0.1 38.10 ± 0.8 ** 60.95 ± 12.0 ** 0.89 ± 0.3 99.17 ± 3.1 **
C. albicansfluR 0.09 ± 0.04 17.37 ± 2.3 ** 53.30 ± 5.6 ** 77.95 ± 11.7 ** 99.17 ± 5.4 **
§ Values of cells with PI-positive phenotype are given in % of all cells counted (100%). ** p ≤ 0.005.
These data were confirmed by using CFU determinations after the exposure of C. albicans cells to
increasing PAFC concentrations (2.5–10 µM) corresponding to 1 × IC90, 2 × IC90 and 4 × IC90 in a time
course (1 h, 8 h, 24 h) (Figure 6). In C. albicansfluS, only 21% ± 2.0% survived the 8-h treatment with
1 × IC90, but after 24 h of exposure the CFU increased again to 49.5% ± 2.5%, indicating that surviving
cells had resumed growth (Figure 6A). In contrast, 1 × IC90 PAFC treatment of C. albicansfluR gave higher
CFU numbers (31.0% ± 0.7%) after 8 h, but very few cells survived the 24-h treatment (1.1% ± 0.001%)
(Figure 6B). This time-dependent trend was strain specific and apparent at all concentrations tested.
These results comfirm the data generated by FACS and suggest that while PAFC killed C. albicansfluS
cells quickly, the survivors of the treatment proliferated again. In contrast, PAFC had a delayed action
on C. albicansfluR but was ultimately more effective as a fungicide.
3.10. Intracellular ROS Induction by PAFC
Studies on the mode of action of fungal AMPs have shown that their activity is often closely linked
with the induction of iROS [13,35,36]. The formation of iROS in Candida cells in response to PAFC was
therefore investigated by fluorescence microscopy (Supplementary Materials, experimental procedures).
C. albicans cells exposed to 1 × IC90 PAFC (2.5 µM) for 8 h were loaded with the non-fluorescent dye
dichlorodihydrofluorescein diacetate (H2DCFDA). In the presence of iROS, this compound is converted
intracellularly to the fluorescent dichlorofluorescein (DCF). As depicted in Figure 7, both C. albicans
strains suffered from iROS induction by PAFC, just like the positive control cells, which had been
exposed to 10 µg mL−1 of the ROS inducing polyene drug nystatin. Untreated control cells did not
show any DCF specific signal (Figure 7).
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Figure 6. Candid cidal activi y of PAFC. FU of (A) C. lbic sfluS and (B) C. a bicansfluR cells after
PAFC treatment (2.5–10 µM) for 1 h, 8 h and 24 h. Untreated cells served as growth control and the
CFU counts were set to be 100% surviving cells. The mean ± SD (technical quadruplicates of one
representative experiment out of two biological replicates) is shown. A two-sample Student’s t-test was
applied to calculate the significant difference between the treated samples compared to the untreated
growth control (p ≤ 0.005 for all values shown, except for * p < 0.1).
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Figure 7. Induction of iROS by PAFC. Fluorescence microscopy of DCF-positive C. albicansfluS and
C. albicansfluR cells to visualize iROS burden after exposure to 1 × IC90 (2.5 µM) PAFC for 8 h at 30 ◦C
and continuous shaking at 160 rpm. The samples were washed in PBS before incubation for 30 min with
H2DCFDA (5 ng µL−1). Excess of fluorescent dye was removed by washing in PBS and the cells were
mounted on glass slides for evaluation of iROS induction by fluorescence microscopy. Cells without
treatment and exposed to nystatin (10 µg mL−1) were used as negative and iROS-positive controls,
respectively. The merged images show the DCF signal (green) superimposed with the Candida cells
visualized with brightfield microscopy. One representative experiment out of three independent
experiments is shown. Scale bar, 5 µm.
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3.11. Testing of Serum–, Ion–, Thermotolerance and Hemolytic Activity of PAFC
The tolerance of PAFC to serum compounds, high ion concentrations and extreme temperature as
well as the lack of adverse effects in the host are important prerequisites for considering this AMP for a
potential medical application in the future. The presence of 5–15% inactivated fetal calf serum in the
medium reduced PAFC activity against C. albicansfluS in a dose-dependent manner (Figure 8). Similarly,
the supplementation of the growth medium with 1.25–10 mM MgCl2, NaCl and CaCl2 counteracted
the PAFC activity in a concentration dependent manner, with PAFC being most sensitive to MgCl2
(Figure S9). The heating of PAFC to 95 ◦C for 5 min and cooling to 25 ◦C had no adverse effect on its
antifungal efficacy with retention of an IC90 of 2.5 µM by C. albicansfluS. PAFC reduced the fungal
growth after 24 h of incubation to 7.5 ± 2.7% and to 5.8 ± 4.2% before and after its thermal treatment,
respectively, which underlined its high thermotolerance. Finally, PAFC showed no hemolytic activity
when tested on sheep erythrocytes in an agar diffusion assay using Columbia blood agar plates
(Figure S10).
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Figure 8. Serum sensitivity of PAFC. The activity of 0.5 × IC90 (1.25 µM), 1 × IC90 (2.5 µM) and
2 × IC90 (5.0 µM) PAFC was tested on C. albicansfluS in the presence of increasing concentrations
(0–15%) of inactivated fetal calf serum in a microdilution broth assay. Candida cells without PAFC
treatment (0 µM) were used as control representing 100% growth in the presence of 0–15% serum.
The mean ± SD (technical triplicate of one representative experiment out of two biological replicates) is
shown. A two-sample Student’s t-test was applied to calculate the significant difference between the
serum-treated samples compared to the untreated growth control (* p ≤ 0.05 and ** p ≤ 0.005).
4. Discussion
We have predicted the structure, studied the expression and characterized the antifungal mode
of action of PAFC, which phylogenetically belongs to the BP group and represents—apart from
PAF and PAFB [8,9,13,37]—the third and previously uncharacterized AMP from the industrial strain
P. chrysogenum Q176.
Similar to the crystal structure of the P. brevicompactum BP, in silico analysis of PAFC suggested
a β-fold structure containing five antiparallel β-strands. Notably, for PeAfpC, a β-sheet structure
composed of only three β-strands was predicted [12]. This discrepancy could result from the different
in silico approach and prediction software applied to model the proteins. The disulfide bonds in
cysteine-rich AMPs mediate high tolerance to harsh environmental conditions [38]. For Pc-Arctin,
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a high thermal stability but low ion tolerance and low proteolytic stability has been reported [10].
In line with this observation, PAFC showed a high sensitivity to serum and ions but thermal tolerance
under the experimental conditions applied. The positively charged funnel-like opening predicted for
PAFC could be involved in protein function, such as ligand binding and/or interaction with negatively
charged membrane compounds of the fungal target cells, as suggested for this motif in BP [30,39,40].
A detailed analysis by nuclear magnetic resonance to resolve the PAFC solution structure is in progress.
The presence of the pafC transcripts in the mycelium of shaking submersed and surface cultures
grown on solid medium, but not in dormant conidia or germinated conidia, indicated that PAFC
might play a role after colony establishment in fungal growth and/or differentiation of P. chrysogenum.
This assumption was supported by the finding that pafC transcription started in the mycelia of surface
cultures at the onset of sporulation.
It is generally hypothesized that AMPs from filamentous fungi—apart from their antifungal
activity—fullfill additional functions in the host during adaptation to environmental conditions [41,42].
In P. chrysogenum roles of PAF and PAFB were reported in sensing/signaling during growth,
differentiation and/or asexual sporulation [8,24,41] but detailed knowledge at the molecular level of
the role of fungal AMPs in adaptive responses is still lacking. However, we have shown for the first
time that the three P. chrysogenum AMPs PAF, PAFB and PAFC are abundantly secreted together into
the exudate of old sporulating surface colonies grown on rich medium. Generally, fungal exudates
contain secondary metabolites, enzymes and other by-products that are assumed to support cell
survival under unfavorable environmental conditions. These liquid reservoirs can be reabsorbed
when needed [43]. Indeed, these droplets and the exudate below the colony disappeared with longer
incubation. This observation could indicate that exudate production in P. chrysogenum is related to
nutrient access and the age of the mycelium.
The amount of endogenous PAFC was insufficient to provide the purified protein needed for
characterization of its antifungal activity. Instead, we used a well-established P. chrysogenum-based
expression system to produce recombinant PAFC. We obtained protein yields better than those achieved
previously with other recombinant AMPs using this system [9,12,13,26,27,44–48].
The BP cluster AMPs were poorly characterized with regard to their potential medical applicability.
Our study shows the in vitro growth inhibitory efficacy of a BP cluster protein against opportunistic
pathogenic fungi of the genus Candida. The anti-Candida effective concentration range of PAFC
resembled that of PAF and PAFB, the latter showing the highest efficacy against the NAC species
C. glabrata, C. krusei and C. parapsilosis (IC90 0.6 µM) with PAF being most effective against C. parapsilosis
(IC90 2.5 µM) [7,9]. The growth inhibitory activity of Pc-Arctin from P. chrysogenum A096 was tested on
the common environmental mold Paecilomyces variotii, the plant pathogen Alternaria longipes, and the
biofungicide Trichoderma viride [10]. For the P. brevicompactum BP, growth inhibitory activity against
Saccharomyces cerevisiae was reported [11], whereas no antifungal activity was detected for PeAfpC [12].
To dissect in more detail the antifungal mode of action of PAFC, we used two strains of the most
prevalent human pathogenic yeast, the fluconazole-sensitive C. albicansfluS and the fluconazole-resistant
clinical isolate C. albicansfluR [16], whereby the latter strain still proliferated in the presence of the highest
fluconazole concentration applied in this study. The molecular basis for the fluconazole resistance of
C. albicansfluR is not known and subject of current investigations.
Both C. albicans strains exhibited the same IC90 value (2.5 µM). However, the broth microdilution
assays show effects on growth but not on the killing potential of an antifungal compound. Therefore, we
applied plating assays for CFU determination plus SEM, CLSM and FACS to visualize and quantitate
the fungicidal efficacy of PAFC. Our data indicated that PAFC acted in a fungicidal way on sessile
and planktonic cells of both C. albicans strains under the test conditions applied, though the efficacy
was higher against C. albicansfluR than against C. albicansfluS. After 24 h of incubation PAFC killed
more planktonic and sessile cells of C. albicansfluR than of C. albicansfluS. Interestingly, cells of the
latter strain resumed growth after 24 h of PAFC exposure, which suggests an adaptive response
to PAFC treatment. In contrast, C. albicansfluR might lack the ability to respond adequately to the
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antifungal PAFC action [49]. It is known that drug resistance can be acquired at the cost of cellular
fitness, leading to a disadvantage for the organism under unfavorable conditions in the absence of the
specific drug [50]. Further investigations are needed to clarify, if azole-resistant C. albicans strains are
generally more susceptible to AMPs than sensitive ones. In this respect, the comparison of several
well characterized drug-resistant clinical isolates with standard strains for PAFC susceptibility or the
screening of drug-sensitive parental and resistant daughter strains isolated from the same patient
could be supportive.
The cell damage induced by PAFC resembled that reported for the candidacidal-acting Neosartorya
fischeri antifungal protein 2 (NFAP2) [16]. However, our qualitative analysis by CLSM revealed that
cell death in C. albicans requires PAFC uptake and cytoplasmic localization before plasma membrane
permeabilization occurs pointing towards an intracellular target. This mode of action strongly resembles
that of P. chrysogenum PAF and PAFB [9,25,27], the N. fischeri antifungal protein NFAP [48] and synthetic
antifungal peptides, e.g., PAF26 [51]. Notably, PAFC activity was closely linked to the accumulation of
iROS, which is generally recognized as a trigger for apoptotic cell death in C. albicans [52]. Indeed,
oxidative stress seems to be a common phenotypic marker of AMP-mediated antifungal activity as
reported for PAF [13,53], several plant defensins [54,55] and synthetic antifungal peptides [13,56].
5. Conclusions
The emerging drug resistance of human pathogenic fungi and the limited number of antifungal
drugs requires the urgent identification of new antifungal compounds with novel mechanism of
action [2]. We have shown that PAFC is a promising new antifungal biomolecule. It can be
produced in high yields and quality in P. chrysogenum, a generally recognized as safe organism [57].
The recombinant PAFC effectively inhibited the growth of the opportunistic human pathogen C. albicans
and exhibited candidacidal activity with high efficacy against a fluconazole-resistant C. albicans
clinical isolate. The high thermotolerance and the lack of hemolytic activity further supports its
potential applicability in clinical therapy. Similar, to many other cysteine-rich, cationic AMPs from
filamentous fungi [8,10,27,53,58] PAFC also exhibited serum and cation sensitivity, which may hamper
an intravenous application to combat severe systemic fungal infections. Instead, PAFC might help to
develop new drugs for topical prevention or cure of fungal nail, skin and mucosal infections while
repeated application of PAFC may be required to maintain its candidacidal efficacy. Furthermore,
rational design could be a promising option to improve the antifungal efficacy of PAFC and overcome
features that limit its potential for medical application.
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